References
- American Cancer Society. Cancer facts & figures. [cited 2021 Nov 20]. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html
- Aschebrook-Kilfoy B, Ward MH, Sabra MM, et al. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid. 2011;21(2):125–134.
- Grande E, Zafon, Carles and Capdevila, Jaume, et al. Thyroid cancer: molecular aspects and new therapeutic strategies. J Thyroid Res. 2012;2012:847108.
- Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009;18(3):784–791.
- Takahashi S, Kiyota N, Yamazaki T, et al. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol. 2019;15(7):717–726.
- National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines R). Thyroid Carcinoma. Version 2. 2017. www.nccn.org/professionals/physiciangls/pdf/thyroid.pdf
- Busaidy NL, Cabanillas ME. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res. 2012;2012:618985.
- Pacini F, Ito Y, Luster M, et al. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Rev Endocrinol Metab. 2012;7(5):541–554.
- Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–2899.
- Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339(6219):58–61.
- Hattori K, Dias S, Heissig B, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med. 2001;193(9):1005–1014.
- Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003;100(8):4712–4717.
- Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14(2):e0212513.
- Ott PA, Hodi FS, Buchbinder EI. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol. 2015;5:202.
- Taylor MH, Lee C-H, Makker V, et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol. 2020;38(11):1154–1163.
- Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14(17):5459–5465.
- Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122(3):664–671.
- Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747.
- Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630.
- Eisai Co, Ltd. Eisai receives approval in Japan for anticancer agent Lenvima(lenvatinib mesylate) as treatment for unresectable thyroid cancer [press release]. cited 2018 Mar 26]; 2018 Mar 26: https://www.eisai.com/news/enews201520pdf.pdf.
- Tahara M, Brose MS, Wirth LJ, et al. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. 2019;106:61–68.
- Cho SH, Han S, Ghim J-L, et al. A randomized, double-blind trial comparing the pharmacokinetics of CT-P16, a candidate bevacizumab biosimilar, with its reference product in healthy adult males. BioDrugs. 2019;33(2):173–181.
- Buske C, Ogura M, Kwon H-C, et al. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements. Future Oncol. 2017;13(15s):5–16.
- United States Food and Drug Administration. Avastin prescrib ing information. 2018. [cited 2018 November 22]; https://www.gene.com/download/pdf/avastin_prescribing.pdf.
- European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. cited 2018 November 22: https://www.ema.europa.eu/documents/scientifc-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf.
- U.S. Food and Drug Administration. Lenvima (lenvatinib) capsules, for oral use [package insert].Woodcliff. Lake NJ: Eisai Inc.; 2017.
- Shumaker R, Aluri J, Fan J, et al. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers. Int J Clin Pharmacol Ther. 2014;52(4):284–291.
- Facciorusso A, Tartaglia N, Villani R, et al. Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis. Am J Transl Res. 2021;13(4):2379–2387.
- Guidance for Industry BIOEQUIVALENCE GUIDANCE. https://www.fda.gov/media/70115/download
- Product-specific bioequivalence guidance [cited 2015 July 10]: https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/product-specific-bioequivalence-guidance
- Shumaker R, Aluri, J and Fan, J Martinez, G, et al. Effects of ketoconazole on the pharmacokinetics of lenvatinib (E7080) in healthy participants. Clin Pharmacol Drug Dev. 2015;4(2):155–160.
- Shumaker RC, Aluri, J and Fan, J Martinez, G, et al. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. Clin Drug Investig. 2014;34(9):651–659.
- Shumaker R, Aluri, J and Fan, J Martinez, G, et al. Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration. J Clin Pharmacol. 2015;55(3):317–327.
- Clinical pharmacology review on LENVIMA (lenvatinib) for FDA supplement approval for NDA 206947/S-003 dated November 16, 2015. [cited 2015 NOV 16]; https://www.gene.com/media/news-features
- Approved Drug Products with Therapeutic Equivalence Evaluations 41st Edition (Orange Book). cited 2021 NOV 07; https://www.fda.gov/media/71474/download
- LENVIMA® (lenvatinib) capsules, for oral use Initial U.S. Approval: 2015 [ cited 2015; https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206947s019lbl.pdf
- Sato J, Satouchi, M Itoh, S Okuma, Y and Niho, S, et al. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol. 2020;21(6):843–850.
- Nakamichi S, Nokihara, H Yamamoto, N Yamada, Y Honda, K, et al. A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015;76(6):1153–1161.
- Hong DS, Kurzrock R, Wheler JJ, et al. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Clin Cancer Res. 2015;21(21):4801–4810.
- Guidance for Industry BIOEQUIVALENCE GUIDANCE. [cited 2022 01]; https://www.fda.gov/media/70115/download